Fda Dietary Supplement Adverse Event Reporting Guidance

This is not exactly a new document and in reality this represents a minor revision of the 2012 guidance on postmarketing adverse event reporting.
Fda dietary supplement adverse event reporting guidance. In response to rapidly changing conditions due to the covid 19 pandemic the us food and drug administration fda published a revised guidance on postmarket adverse event reporting requirements. The revised guidance applies to drugs biologics medical devices combination products and dietary supplements. The guidance issued march 19 revises and replaces fda s february 2012 final guidance titled postmarketing adverse event reporting for medical products and dietary supplements during an influenza pandemic to clarify that the guidance applies not just to an influenza pandemic but to any pandemic including covid 19.
Dietary supplements include vitamins minerals herbs amino acids whey protein creatine and weight loss pills. Fda has published a new guidance document on 19 mar 2020 which is entitled. Fda does not approve dietary supplement products before they are sold to the public.
Postmarketing adverse event reporting for medical products and dietary supplements during a pandemic. This guidance provides recommendations to industry regarding postmarketing adverse event reporting for drugs biologics medical devices and dietary supplements during a pandemic.